Core Viewpoint - Silo Wellness Inc. is transitioning to Born Defense Inc., focusing on defense innovation and national security investments, with a listing statement submitted to the Canadian Securities Exchange for review [1][3]. Company Overview - Silo Wellness Inc. will be renamed Born Defense Inc., which will operate as a national security investment issuer committed to ethical defense finance guided by the Just War Doctrine [9]. - The company's restructured business model will focus on trade finance, strategic equity investments, and collateral-backed lending for pre-IPO and critical infrastructure ventures globally [9]. Listing Statement Details - The Listing Statement provides comprehensive disclosure regarding the company's business, assets, financial statements, management team, and strategic direction, which is essential for resuming trading of the company's common shares [2]. - Recent measures to strengthen the financial position include agreements to settle approximately CAD $4.4 million of debt through the issuance of common shares, significantly reducing liabilities [4]. Strategic Direction - Born Defense's strategy is based on Just War principles, emphasizing the protection of individual liberty and responsible industrial stewardship [3]. - The company aims to stabilize and strengthen its public vehicle by converting debt into shares or establishing middle- and long-term payment plans with creditors [5]. Future Steps - The Listing Statement will be available on the company's profile on SEDAR+ once accepted for filing by the CSE, and shareholders will be notified of any required meetings to approve the proposed change of business [5].

Core Insights - Silo Pharma has engaged Fireblocks as the custodian for its institutional crypto treasury platform, focusing on Bitcoin, Ethereum, and Solana [1][2] - The partnership aims to ensure enterprise-grade security and governance standards for managing digital assets, enhancing long-term value for shareholders [2][3] Company Overview - Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, targeting underserved conditions such as stress-induced psychiatric disorders and chronic pain [3] - The company's therapeutic portfolio includes programs for PTSD, fibromyalgia, and preclinical assets for Alzheimer's disease and multiple sclerosis [3] Fireblocks Overview - Fireblocks is recognized for its secure platform that facilitates the transfer of over $6 trillion in digital assets, utilizing a multi-layer security framework [2][4] - The platform supports various financial entities, including exchanges, banks, and hedge funds, enabling them to scale their digital asset operations securely [4]

Core Insights - Silo Pharma Inc. has engaged Fireblocks as the custodian for its institutional crypto treasury platform, aiming to enhance security and governance standards [1][3] - Fireblocks has facilitated the secure transfer of over $6 trillion in digital assets, showcasing its capability in the digital asset space [2][3] - Silo Pharma's initial purchases of Ethereum (ETH) and Solana (SOL) tokens mark the beginning of its cryptocurrency treasury strategy, which was launched in August [5][6] Company Developments - The partnership with Fireblocks is expected to provide enterprise-grade security for Silo's crypto treasury platform [1][3] - Silo Pharma has appointed Corwin Yu as the first member of its Crypto Advisory Board to lead its cryptocurrency treasury strategy [5] - The company has also acquired AI-powered market intelligence technology to enhance decision-making capabilities [6] Market Context - The Fireblocks Network allows various financial entities, including exchanges and hedge funds, to securely scale their digital asset operations [4] - Silo Pharma's strategy aims to incorporate cryptocurrency into its treasury holdings and supports broader initiatives in blockchain and real-world asset tokenization [5]

Core Insights - The company has initiated its cryptocurrency treasury strategy by purchasing Ethereum (ETH) and Solana (SOL) tokens, marking a significant step towards integrating digital assets into its treasury holdings [2][3] - This investment reflects the company's belief in the long-term value of digital assets and the potential of blockchain technology to influence the biotechnology sector [2][3] - The CEO emphasized the company's commitment to decentralized finance and smart contract platforms, stating that the tokens will be staked for revenue generation and capital appreciation to support biopharmaceutical asset development [3] Company Overview - Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved medical conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases [4] - The company's portfolio includes innovative programs targeting PTSD, fibromyalgia, chronic pain, Alzheimer's disease, and multiple sclerosis, with research conducted in collaboration with leading universities and laboratories [4] Strategic Initiatives - The company's cryptocurrency treasury strategy aims for multi-chain asset growth and lays the groundwork for broader blockchain and real-world asset tokenization initiatives [2] - The accelerating adoption of digital assets by institutional investors and global enterprises supports the company's comprehensive digital assets strategy [3]

Core Insights - Saucony is launching its AW25 collection from the Saucony SILO line, which emphasizes the blend of heritage, luxury, and performance in footwear design [1][2] - The collection will be available globally starting September 18, 2025, following its initial reveal at Paris Fashion Week in June [1][3] Product Details - The AW25 collection features two new silhouettes, Momentum and Trekker, alongside updated versions of popular styles, showcasing a balance of heritage and material innovation [3][5] - The design process involved collaborations with creative professionals, enhancing the storytelling aspect of the brand's legacy [2][3] Brand Background - Saucony, a division of Wolverine World Wide, Inc., is recognized for its innovative technologies and commitment to inspiring a running culture [4] - The brand has a long history, founded in 1898, and aims to blend innovation, style, and culture in its products [4]

Core Insights - Silo Pharma, Inc. has received a Japanese patent for its lead asset SPC-15, an intranasal treatment for post-traumatic stress disorder (PTSD), which enhances its intellectual property portfolio [1][2] - The company is collaborating with Columbia University for the development of SPC-15, which is a serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders [2][3] - Silo Pharma's therapeutic focus includes addressing conditions such as PTSD, chronic pain, and central nervous system diseases, with a diverse portfolio of innovative programs [3] Patent and Intellectual Property - The Japan Patent Office granted patent number 7683882 to Columbia University for the invention titled "Prophylactic efficacy of serotonin 4 receptor agonists against stress," which is exclusively licensed to Silo [1] - This patent adds to Silo's international intellectual property portfolio, reinforcing the protection for SPC-15 [2] Product Development - SPC-15 is positioned for potential eligibility under the FDA's streamlined 505(b)(2) regulatory pathway, which could expedite its approval process [2] - The company is conducting preclinical studies in collaboration with Columbia University and holds exclusive global rights for the development and commercialization of SPC-15 [2] Company Overview - Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company [3] - The company's portfolio includes other programs such as SP-26 for fibromyalgia and chronic pain, as well as preclinical assets targeting Alzheimer's disease and multiple sclerosis [3]

Core Viewpoint - Silo Pharma, Inc. has received a patent for its lead asset SPC-15, which is an intranasal treatment for post-traumatic stress disorder (PTSD), enhancing its intellectual property portfolio and supporting clinical trial development plans [1][2][3]. Company Overview - Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases [4]. - The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis [4]. Product Details - SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders like PTSD and anxiety [3]. - The product has potential eligibility for the FDA's streamlined 505(b)(2) regulatory pathway, which could accelerate its approval process [3]. - Silo Pharma collaborates with Columbia University for preclinical studies and holds exclusive global rights for the development and commercialization of SPC-15 [3].

Company Overview - Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases [6] - The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis [6] Alzheimer's Disease Therapeutic Development - Silo Pharma announced the publication of preclinical research for its Alzheimer's disease therapeutic, SPC-14, in the journal Alzheimer's Research & Therapy [1] - The study titled "Combinatorial targeting of NMDARs and 5-HT4Rs exerts beneficial effects in a mouse model of Alzheimer's disease" indicates that the combined administration of (R,S)-ketamine with prucalopride is a novel multi-modal therapeutic strategy to treat cognitive decline in Alzheimer's disease [2] - The results showed that the SPC-14 formulation improved cognitive decline by increasing memory retrieval in a fear conditioning model in mice, identifying SPC-14 as a promising drug combination for therapeutic use in Alzheimer's disease [3] Market Potential - The Alzheimer's disease treatment market is projected to grow to $30.8 billion by 2033, with a compound annual growth rate (CAGR) of 18.8% [4] - SPC-14 was developed under a sponsored research agreement with Columbia University, and Silo Pharma entered into an exclusive global license agreement with the university to further develop, manufacture, and commercialize SPC-14 [4] Therapeutic Mechanism - SPC-14 is a novel intranasal therapeutic that targets glutamate receptor NMDAR and serotonin type 4 receptor 5HT4 to treat cognitive and neuropsychiatric symptoms in Alzheimer's disease [5] - In preclinical studies, SPC-14 was effective against luteinizing hormone stress, attenuating learned helplessness, perseverative behavior, and hyponeophagia, which is a measure of anxiety [5]

Core Insights - Silo Pharma, Inc. announced the publication of preclinical research for its Alzheimer's disease therapeutic, SPC-14, in a leading scientific journal, Alzheimer's Research & Therapy [1][2] - The study indicates that the combination of (R,S)-ketamine and prucalopride is a novel therapeutic strategy for treating cognitive decline in Alzheimer's disease [2] - SPC-14 has shown promising results in improving cognitive decline in preclinical models, suggesting its potential as a therapeutic option for Alzheimer's disease [3] Company Overview - Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company focused on addressing underserved conditions, including Alzheimer's disease [5] - The company has developed SPC-14 under a sponsored research agreement with Columbia University and has an exclusive global license to further develop and commercialize the product [4] - Silo's portfolio includes other innovative programs targeting conditions such as PTSD and chronic pain, indicating a broad therapeutic focus [5] Market Potential - The Alzheimer's disease treatment market is projected to grow to $30.8 billion by 2033, with a compound annual growth rate (CAGR) of 18.8% [4][7] - SPC-14 targets glutamate receptor NMDAR and serotonin type 4 receptor 5HT4, addressing cognitive and neuropsychiatric symptoms associated with Alzheimer's disease [4]

Core Insights - Silo Pharma, Inc. announced positive bioanalytical and safety/toxicology results for its SPC-15 intranasal spray formulation, meeting FDA safety standards for clinical trials [1][2] - The study demonstrated that SPC-15's intranasal administration has comparable systemic exposure to oral administration while showing no identified toxicities, supporting its potential as a PTSD therapeutic [2][3] - The company is pursuing a 505(b)(2) regulatory strategy to streamline the FDA approval process by leveraging existing safety and efficacy data from approved drugs [3] Company Developments - Silo is conducting an IND-enabling GLP-compliant toxicology study and evaluating clinical CRO sites for first-in-human trials of SPC-15 [4] - The company focuses on addressing underserved conditions, including PTSD, chronic pain, and CNS diseases, with a portfolio that includes SPC-15 and other innovative programs [5] Market Insights - The PTSD market size was valued at $1.8 billion in 2024 and is projected to reach $3.2 billion by 2034, driven by increased focus on mental health and personalized treatment solutions [5]